Studies have shown that dysregulated expression of miRNAs is a major underlying event in the onset and progression of many metabolic diseases. The pathological role of miR-548c-3p in various cancer types, including breast cancer, glioma, prostate cancer, and gastric cancer, has been documented. However, experimental evidences validating the role of miR-548c-3p in the development of metabolic diseases are still lacking, and no data is available on its diagnostic potential for metabolic syndrome (MS). Recently, we predicted the involvement of miR-548c-3p in the pathogenesis of MS and its progression to cardiovascular diseases (CVD) via the regulation of target genes necessary for the proper function of insulin resistance, mTOR, and JAK/STAT signaling pathways. Therefore, we deemed it necessary to engage in wet laboratory analysis and validate these claims in patients with metabolic syndrome compared to healthy individuals.